Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
about
RETRACTED: Selective killing of cancer cells by a small molecule targeting the stress response to ROSBRCAness: finding the Achilles heel in ovarian cancerDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerDNA damage response and prostate cancer: defects, regulation and therapeutic implicationsBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsTreatment options in recurrent ovarian cancer: latest evidence and clinical potential.PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsPersonalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based SelectionTIRR regulates 53BP1 by masking its histone methyl-lysine binding functionDynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsPoly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer.Extensive gene-specific translational reprogramming in a model of B cell differentiation and Abl-dependent transformationThe level of Ets-1 protein is regulated by poly(ADP-ribose) polymerase-1 (PARP-1) in cancer cells to prevent DNA damage.Genetically engineered mouse models of PI3K signaling in breast cancer.Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-γNew concepts in breast cancer genomics and geneticsEfficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.African flora has the potential to fight multidrug resistance of cancerNF-κB signaling mediates acquired resistance after PARP inhibition.Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis.Classification, molecular characterization, and the significance of pten alteration in leiomyosarcoma.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.Adenanthin targets peroxiredoxin I/II to kill hepatocellular carcinoma cells.PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expressionHigh-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinomaDual roles of PARP-1 promote cancer growth and progression.mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors.Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value.New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches.Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver.Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell linesMechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.
P2860
Q24607147-E05C57F2-37A2-4EC3-9D7F-5888D85ABF25Q24630872-D2F3BD2C-0C67-41C6-92DA-3D758DA7B945Q26776513-6268640B-F056-4AD9-B3FA-AE04C65DC080Q26783551-5F36DADC-F89D-41BC-AF42-0C946C4EECD2Q26829155-B047944B-40D7-4D9B-942F-3CF5BE60F1E8Q26852274-2E940A89-C23F-466A-80B4-C7E3588FBF28Q27692699-38BB1F44-7583-4F60-8583-0BFCF3041DD6Q28071345-0836F3F4-A58E-460B-BDC4-CF5C44EA27F0Q28294205-8F09A7AB-51EB-4D50-B85C-7B37748E7A9BQ28552598-E3847666-474C-4B22-8DA8-F25AB5061442Q29465810-80BFFAF8-4205-4A6C-9A06-C9426962B993Q33584594-2B3AF418-BAEC-43D6-BC1C-53FDA73CE871Q33618910-EDCAFAF0-FD39-4ADB-84EC-43724B9C897EQ33621410-793D21C1-40EA-4269-A601-10B0C091F65AQ34302309-DBC5F291-9F56-49EF-8F40-53E24ACF659AQ34327567-95F4D83F-F7B1-4238-A273-118F7E2FFC9FQ34332175-F8C074DC-CC99-49C1-AB17-CBC097864AEEQ34989005-C4C2659B-8E0D-4DF0-9348-0BBD45986C05Q35258057-AA128253-7E8C-4542-B070-B06E176E107FQ35374807-91453F51-0C50-4B7E-A754-F62455D96ED1Q35549014-3DA19995-1C8D-46FC-9370-6343E3F6BA14Q35551882-DE22C5A8-79F4-4F20-980F-3D7661625715Q35588352-1B1D9AE4-770C-47BE-B954-55B188A94614Q35604127-68C99D83-4A62-4628-882A-DD4B89139695Q35788748-2094B836-92B0-4C71-901A-717961787E30Q35837949-2A98B72C-8116-4C92-82EB-DDA03B9E10B4Q35879098-A927260C-1069-4F46-82AF-6DBF2F2A9FAFQ35895214-F59BED32-31D6-4CE5-8E46-BDEDE041B844Q35909678-E891906D-66EA-40B6-BE1C-99AB750ED263Q35966184-DB4F177E-C6D2-4017-BFFF-33EEE46A0365Q36020900-21F06F84-D52C-4B5B-8E68-DDC3891AA353Q36231927-698BCB60-202A-47A4-9AFE-F5D623EB87BEQ36460391-20975D14-234D-481B-9C6A-8F859A23669CQ36874139-F9EA96B3-9CDB-4FDF-8B25-62977967AD11Q37092210-D3650E16-4DB1-48E8-8C0F-2273855C21BBQ37135340-BFCAD11D-5C98-4822-BEE1-1A6B4CA2D6E9Q37155964-4B1C28BE-F4FA-43BE-BBA5-1AE5F46B9D15Q37174451-B5EF96FD-22CA-448E-97C3-5E6B8B8E1FA6Q37269217-A8D004A1-6EB9-441F-9B32-F79BD70A8B72Q37309889-7504E28C-0696-469B-B8D7-725437BC47FA
P2860
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Poly(ADP-ribose) polymerase (P ...... lethal strategy in the clinic.
@en
type
label
Poly(ADP-ribose) polymerase (P ...... lethal strategy in the clinic.
@en
prefLabel
Poly(ADP-ribose) polymerase (P ...... lethal strategy in the clinic.
@en
P2093
P2860
P356
P1433
P1476
Poly(ADP-ribose) polymerase (P ...... lethal strategy in the clinic.
@en
P2093
Craig P Carden
Johann S de Bono
Shahneen K Sandhu
Timothy A Yap
P2860
P356
10.3322/CAAC.20095
P407
P577
2011-01-04T00:00:00Z